



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 13, 2019

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (E) **Mumbai -400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that CX Securities Limited (*Investor*) has divested majority of its investment in the Company, over a period of time, by selling the equity shares in the open market through the stock exchanges. The Investor had invested in the Company by acquiring 17,00,000 equity shares of Rs.10/- each, which were allotted on preferential basis on November 29, 2013. Thereafter, the Investor indicated its desire to incentivize the Company for increase in shareholders' value through its performance.

In consideration of the investment opportunity provided by the Company to the Investor in November 2013, the subsequent performance of the Company, and the resultant increase in the shareholder value, the Investor intended to pay incentive to the Company. Consequently, the Investor has agreed to pay USD 6.83 Million (approximately INR 48.00 crores) to the Company as an incentive in compliance with applicable laws. The Company will take necessary steps in due course for receiving the said payment from the Investor.

Thanking you

Yours faithfully
For Natco Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)